Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT02251275 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1803

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

DRUG: Tolvaptan

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.